Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.

Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 05; 98(7):441-50.

View in: PubMed

subject areas

Aged
Anticarcinogenic Agents
Antineoplastic Agents
Carcinoma, Squamous Cell
Disease-Free Survival
Drug Administration Schedule
Female
Head and Neck Neoplasms
Humans
Isotretinoin
Male
Multivariate Analysis
Neoplasm Staging
Neoplasms, Second Primary
Odds Ratio
Patient Selection
Proportional Hazards Models
Risk Factors
Smoking
Survival Analysis
Treatment Failure

authors with profiles

Everett E. Vokes